US pre-clinical biotech start-up Montara Therapeutics, which is pioneering brain-selective therapies for CNS diseases, has announced the closing of a $20 million oversubscribed expansion of its Series Seed financing.
The company noted that the financing round, which brings Montara’s total seed funding to $28 million, includes increased participation from all existing investors, including founding investor SV Health Investors’ Dementia Discovery Fund, Two Bear Capital, Dolby Family Ventures, and KdT Ventures, along with new investments from BEVC and additional investors.
“As we take this next critical step towards the clinic, we’re thrilled by upsized commitments from our existing investors and welcome the new investors to our syndicate,” said Nicholas Hertz, founder and chief executive of Montara.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze